1. Scrip
  2. >>Business

BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal

Bets on China Data, Differentiation Strategy

 
• By Brian Yang

BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.

Beigene Suzhou Opening
BEIGENE UNVILES SUZHOU PRODUCTION SITE FOR ONCOLOGY PRODUCTS • Source: Beigene

Days after BeiGene, Ltd. obtained national insurance coverage for the drug in China, the Beijing-based firm has reached a partnership with Swiss pharma giant Novartis AG to develop and commercialize its anti-PD-1 antibody tislelizumab in the US, Canada, Mexico, Russia, Japan, the European Union, the UK and other European markets.

BeiGene will receive $650m upfront and is eligible for up to $1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip